Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Eur J Obstet Gynecol Reprod Biol ; 131(1): 61-67, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17113210

RESUMEN

OBJECTIVE: The aim of the study was to compare the effect of spironolactone (antagonist of mineralocorticoid and androgen receptors) versus spironolactone plus licorice (agonist of mineralocorticoid receptors and mild inhibitor of androgen synthesis) on plasma renin activity, aldosterone and androgen levels in women with polycystic ovary syndrome (PCOS). STUDY DESIGN: Thirty-two women with PCOS were divided into two groups: 16 received 100 mg spironolactone and 16 spironolactone plus 3.5 g of licorice a day. Blood pressure, body mass index, serum electrolytes, plasma renin activity, plasma aldosterone and cortisol, serum testosterone, and urinary tetrahydrocortisol/tetrahydrocortisone ratio were measured before and during treatment. RESULTS: Mean blood pressure was significantly reduced during spironolactone treatment, while it was unchanged in women receiving spironolactone plus licorice. Twenty percent of women treated with spironolactone and none treated with the addition of licorice complained of symptoms related to volume depletion. Consistently, the activation of the renin-aldosterone system was significantly lower during spironolactone plus licorice than with spironolactone alone. The prevalence of metrorrhagia was lower in the combined therapy. CONCLUSIONS: In patients with PCOS the mineralocorticoid properties of licorice can reduce the prevalence of side effects related to the diuretic activity of spironolactone.


Asunto(s)
Glycyrrhiza , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Espironolactona/uso terapéutico , Adulto , Aldosterona/metabolismo , Andrógenos/metabolismo , Presión Sanguínea/fisiología , Diuréticos/efectos adversos , Diuréticos/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Antagonistas de Receptores de Mineralocorticoides/efectos adversos , Mineralocorticoides/antagonistas & inhibidores , Síndrome del Ovario Poliquístico/metabolismo , Síndrome del Ovario Poliquístico/fisiopatología , Receptores de Mineralocorticoides/agonistas , Renina/sangre , Sistema Renina-Angiotensina/fisiología , Espironolactona/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA